Fulgent Genetics, Inc.

FLGT Healthcare Diagnostics & Research

Fulgent Genetics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $322.7 million, up 13.8% from fiscal 2024. In the quarter to June 2026, revenue grew 4.38%, EPS fell 69.4% and free cash flow grew 25.4%, each against the same quarter a year earlier.

19.81 1.53 −7.17%
Market cap
$587.2M
P/E
0.0×
Fwd P/E
−5.8×
Dividend yield
—
F-score
4/9
Altman Z
5.63
Beneish M
−2.35
Dividend safety
n/a
Older periods Sep '25 Dec '25 Mar '26 Jun '26
P/E ratio

+8 more quarters

0.00 0.00 0.00 0.00
P/S ratio
2.20 2.51 1.53 1.77
P/FCF ratio
0.00 0.00 0.00 0.00
P/Operating CF
62.57 (10.35) 69.19 (24.19)
P/B ratio
0.62 0.73 0.47 0.58
Price to Tangible BV
0.72 0.80 0.54 0.67
EV/Sales
1.08 1.53 0.74 1.05
EV/EBITDA
0.00 0.00 0.00 0.00
EV/Operating CF
223.29 (4.85) (2.62) (4.05)
EV/FCF
(17.14) (3.97) (2.08) (3.26)
Quick Ratio
6.17 4.95 3.83 4.49
Current Ratio
7.01 6.48 5.31 6.34
Net Debt/EBITDA
778.06 8.20 9.36 8.82
Debt/Assets
0.00% 0.00% 0.00% 0.00%
Debt/Equity
0.00 0.00 0.00 0.00
Asset Turnover
0.26 0.27 0.27 0.28
Operating CF/Net income
(1.68) 3.34 (0.29) 0.80
Capex/Depreciation
(0.41) 1.05 (1.02) (0.56)
Interest Coverage
(548.21) (2,264.87) (2,036.59) (611.41)
Research and Development Expense of Revenue
16.49% 17.00% 19.93% 17.04%
Selling, General and Administrative Expense of Revenue
41.61% 63.15% 56.10% 49.68%
Intangible Assets out of Total Assets
0.13 0.07 0.12 0.12
Share Based Compensation of Revenue
11.56% 11.13% 13.90% 10.10%
Graham Net Nets
0.60 0.55 0.75 0.63
Graham Number
0.00 0.00 0.00 0.00
Earnings Yield
(6.15%) (7.46%) (15.03%) (13.74%)
Free Cash Flow Yield
(2.86%) (15.36%) (23.05%) (18.06%)
Revenue per Share
2.73 2.71 2.30 3.05
Operating CF per Share
0.36 (2.54) 0.23 (0.85)
Capex per Share
(0.20) (0.16) (0.17) (0.14)
Free Cash Flow per Share
0.16 (2.70) 0.06 (0.99)
Cash per Share
12.22 10.92 8.95 9.18
Shareholders Equity per Share
36.45 35.96 33.81 35.56
Interest Debt per Share
0.00 0.00 0.00 0.00
Book value per Share
36.45 35.96 33.81 35.56
Free Cash Flow
5.06 (83.12) 1.90 (27.62)
Working Capital
434.95 465.52 388.91 383.01
Capital Expenditures
(6.05) (4.98) (5.19) (3.86)
Net Current Asset Value
413.57 443.68 366.83 361.53
EV/EBIT
0.00 0.00 0.00 0.00
Capex to Sales
0.07 0.06 0.07 0.05
Price to Operating Income
0.00 0.00 0.00 0.00
Other line items
Average Receivables
64.25 76.89 70.38 71.06
Average Payables
18.95 18.51 19.68 17.22
Average Assets
1,224.16 1,216.74 1,181.06 1,144.53
Average Common Equity
1,127.83 1,117.94 1,083.46 1,053.81

Fold the line items

Columns are period end dates